These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19682280)

  • 1. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.
    Packer LM; East P; Reis-Filho JS; Marais R
    Pigment Cell Melanoma Res; 2009 Dec; 22(6):785-98. PubMed ID: 19682280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells.
    Smith AG; Lim W; Pearen M; Muscat GE; Sturm RA
    Pigment Cell Melanoma Res; 2011 Jun; 24(3):551-63. PubMed ID: 21362156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.
    Conrad WH; Swift RD; Biechele TL; Kulikauskas RM; Moon RT; Chien AJ
    Cell Cycle; 2012 Oct; 11(20):3724-30. PubMed ID: 22895053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.
    Liu D; Liu X; Xing M
    Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor.
    Hernandez MA; Patel B; Hey F; Giblett S; Davis H; Pritchard C
    Cell Signal; 2016 Jun; 28(6):561-71. PubMed ID: 26898828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
    Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
    Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.
    Puig-Butille JA; Vinyals A; Ferreres JR; Aguilera P; Cabré E; Tell-Martí G; Marcoval J; Mateo F; Palomero L; Badenas C; Piulats JM; Malvehy J; Pujana MA; Puig S; Fabra À
    J Invest Dermatol; 2017 Jun; 137(6):1297-1310. PubMed ID: 28188776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.
    Gerosa L; Chidley C; Fröhlich F; Sanchez G; Lim SK; Muhlich J; Chen JY; Vallabhaneni S; Baker GJ; Schapiro D; Atanasova MI; Chylek LA; Shi T; Yi L; Nicora CD; Claas A; Ng TSC; Kohler RH; Lauffenburger DA; Weissleder R; Miller MA; Qian WJ; Wiley HS; Sorger PK
    Cell Syst; 2020 Nov; 11(5):478-494.e9. PubMed ID: 33113355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.
    Pratilas CA; Taylor BS; Ye Q; Viale A; Sander C; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2009 Mar; 106(11):4519-24. PubMed ID: 19251651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells.
    Fufa TD; Baxter LL; Wedel JC; Gildea DE; ; Loftus SK; Pavan WJ
    Epigenetics Chromatin; 2019 Aug; 12(1):50. PubMed ID: 31399133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
    Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
    Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
    Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
    Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.